EGFR and cancer: Hence, considering that most cancer patients are already susceptible to electrolyte disturbances as well as dehydration secondary to cancer, further studies on risk stratification with appropriate management measures are warranted to improve patient outcomes from EGFR inhibitor therapy [52].